Pan02 (Panc02) Syngeneic Model Service for Pancreas Cancer

The Panc02 syngeneic model service for pancreas cancer is an immune-competent C57BL/6 platform built on the 1984 Corbett carcinogen-induced ductal adenocarcinoma — a poorly differentiated, broadly chemo-resistant tumor that remains the most widely used syngeneic pancreatic cancer system across subcutaneous, orthotopic, and metastatic study formats. Alfa Cytology delivers this model as a complete preclinical capability — covering authenticated Panc02 / Panc02-H7 / luciferase-engineered expansion and banking, Matrigel-cushioned orthotopic implantation, scheduled caliper and in vivo bioluminescence monitoring, and full ductal histopathology with immune-microenvironment and senescence pharmacodynamics — all configured around each sponsor’s chemotherapy, vaccine, checkpoint, stromal, or combination hypothesis.

Overview of Panc02 (Pan02) Syngeneic Model for Pancreas Cancer

Panc02 is the founding syngeneic line of pancreatic ductal adenocarcinoma research, created in 1984 by Corbett and colleagues at the Southern Research Institute through a piece of deliberately primitive technology: cotton threads saturated with the carcinogen 3-methylcholanthrene were implanted directly into the pancreas of female C57BL/6 mice, and the resulting transplantable ductal adenocarcinomas — Panc02 and its sibling Panc03 — became the field’s first durable PDAC tools. The line is poorly differentiated, polygonal and epithelial, and notoriously insensitive to a broad range of cytotoxic agents — a chemo-resistant phenotype that usefully mimics one of human PDAC’s defining clinical traits. One documented caveat frames modern use: Panc02 lacks the canonical human PDAC driver mutations, with no KRAS, TP53, or CDKN2A/p16 lesions and a documented SMAD4 deletion (with KRAS single-nucleotide and SMAD4 mutation reports appearing in the deeper characterization literature) — so genotype-dependent questions are today routed to KPC-derived lines, while Panc02 retains its role for immune, stromal, delivery, and chemoresistance studies.

Fig 1. Tumor-slice transplantation (TST) method for orthotopic Panc02 tumors versus conventional orthotopic injection (OI). (Wang, Jin, et al., 2022)

In vivo, the model’s breadth is its signature. Subcutaneous grafts give rapid, measurable tumors for screening; orthotopic implantation into the pancreatic tail — where the thin pancreatic parenchyma makes cell-suspension extravasation a documented failure mode, prompting the Matrigel-cushion technique developed by Partecke and colleagues — supports bioluminescence-tracked growth and local invasion; and the in vivo-selected Panc02-H7 derivative, established by serial passage through metastatic sites, provides an aggressively metastatic counterpart with distinct TGF-β/SMAD defects. The immunotherapy record is deep and mechanistically rich: intratumoral dendritic-cell vaccination with tumor-RNA-pulsed, α-galactosylceramide-loaded, or glycoepitope-armed DCs proved superior to subcutaneous or intravenous routes in the orthotopic setting; and a systematic CTLA-4 dose-titration study quantified myeloid-derived suppressor cells and tumor-cell PD-L1 while mapping antitumor effect against immune-related adverse events for local versus systemic administration — an early template for checkpoint-delivery design. Gemcitabine at 50 mg/kg weekly is the standard benchmark positive control, and contemporary studies extend the platform into senescence-targeting combinations (etoposide-induced senescence modulated by the Bcl-2 inhibitor navitoclax). Luciferase- and GFP-engineered derivatives support quantitative burden tracking across all formats. For sponsors, Panc02 remains the fastest route into an immune-competent PDAC microenvironment — with its genotype caveat stated plainly and its matched H7 metastatic arm available when dissemination is the question.

Cell Line Information: Panc02 (Pan02)

The table below consolidates the key biological, genetic, and modeling characteristics of the Panc02 line, its Panc02-H7 metastatic derivative, and its engineered variants.

Our Services

A platform with a stated genotype caveat and three validated formats rewards exactly the operational candor Alfa Cytology brings: authenticated Panc02 and H7 banks with documented genetic screening, Matrigel-cushioned orthotopic technique, bioluminescence-tracked monitoring, and endpoint pathology pairing ductal morphology with MDSC/PD-L1 and senescence pharmacodynamics — all under one accountable preclinical operation.

Workflow of Panc02 (Pan02) Syngeneic Model Construction

Construction follows the Corbett/Partecke methodology: Panc02 or derivative cells are expanded under authenticated conditions, implanted subcutaneously or orthotopically into C57BL/6 mice, tracked by caliper and bioluminescence, treated after standardization, and analyzed with PDAC-appropriate efficacy and immune endpoints. The workflow comprises the following stages.

1. Cell authentication and banking: Panc02 or derivative lines are identity-verified (STR), confirmed mycoplasma-negative, and documented for the genetic profile relevant to the study (including the KRAS/TP53/CDKN2A wild-type status and SMAD4 deletion caveat), then expanded into low-passage working banks under the validated RPMI-1640 or DMEM formulation.
2. Cell harvest and formulation: Healthy cultures are trypsinized, washed, counted and viability-checked, then resuspended at approximately 5 × 10⁵ cells in 50 μL of complete medium; for orthotopic arms, cells are mixed 1:1 with cold Matrigel to form the implantation cushion.
3. Anesthesia and implantation: C57BL/6 mice are anesthetized with isoflurane; cells are implanted subcutaneously into the flank, or injected into the exposed pancreatic tail through a small abdominal approach with the Matrigel cushion limiting extravasation.
4. Establishment monitoring and randomization: Flank tumors are measured by caliper from first palpability; orthotopic arms are tracked by in vivo bioluminescence after D-luciferin administration; animals are randomized once tumors reach protocol-specified baselines.
5. Treatment administration: Experimental arms — gemcitabine and cytotoxic combinations, intratumoral or systemic DC vaccines, checkpoint inhibitors with local-versus-systemic dosing, stromal and senolytic agents — proceed per study design with body-weight and toxicity monitoring.
6. Immune and pharmacodynamic monitoring: Tumor and draining-node infiltrates are profiled for MDSCs, Tregs, CD8⁺ T cells, and PD-L1 status by flow cytometry; senescence-arm studies quantify SA-β-gal activity and Cdkn1a/Mdm2 expression in explanted tumors.
7. Endpoint and histopathological analysis: Endpoints integrate tumor-growth inhibition, bioluminescence kinetics, and survival with histopathology (H&E confirming poorly differentiated ductal adenocarcinoma, plus Ki67, α-SMA for stroma, CD8, PD-L1, and marker-specific immunohistochemistry) and ex vivo metastatic mapping where designs require.

Fig 2. Pan02 (Panc02) Syngeneic Model construction workflow.

Case Study-Panc02 (Pan02) Syngeneic Model Development

Alfa Cytology has conducted preclinical programs on the Panc02 platform spanning chemotherapy benchmarking, orthotopic vaccine and checkpoint-delivery evaluation, and matched Panc02-H7 metastatic-arm studies. In these studies, implanted Panc02 tumors were monitored through scheduled caliper and in vivo bioluminescence measurements, treated per randomized regimens, and characterized at endpoint by histopathology with immune-microenvironment and senescence pharmacodynamics. Study-level datasets are available upon request.

Why Choose Alfa Cytology?

Alfa Cytology pairs founding-line operational experience with candid genetic screening, so every Panc02 study is executed with its documented caveat stated, its matched H7 metastatic arm available, and reporting that connects delivery route to immune pharmacodynamics.

• Focused experience with Panc02 in subcutaneous, Matrigel-cushioned orthotopic, and Panc02-H7 metastatic formats.
• A single coordinated team managing cell banking, surgery, in vivo imaging, and endpoint pathology under one quality framework.
• Documented genetic screening at banking (KRAS/TP53/CDKN2A wild-type, SMAD4 deletion) protecting interpretive honesty.
• Design fluency with intratumoral-route vaccines, local-versus-systemic checkpoint titration, and senolytic combinations.
• Transparent milestone reporting and rapid scientific feedback throughout the engagement.

Contact Us

If your pancreas cancer program needs the field’s founding syngeneic PDAC platform — with matched H7 metastatic control and orthotopic delivery-route capability — Alfa Cytology is ready to build the study around your hypothesis. Reach out to us with your regimen and endpoint requirements, or contact us today for a customized proposal and quotation for the Panc02 syngeneic model service.

For research use only. Not intended for any clinical use.